drugset / Trial / NCT02735473

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders

NCT02735473 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled trial of choline supplementation in children with Fetal Alcohol Spectrum Disorders (FASD). The primary outcome measures are cognitive measures.

Timeline

Start
2016-06
Primary completion
2021-09-10
Completion
2021-09-10

Outcome

Met primary endpoint

paper participants receiving choline performed 25% better on EI short-delay adjacent pairs (sequential memory) than those on placebo PMID 39956364 ↗

paper with a steeper increase in scores between 6 and 9 mo (ŷ = -10.06; P = 0.03; 95% CI: -19.13, -0.99). PMID 39956364 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Choline Bitartrate Small molecule 19 mg/kg —